Abstract
Enzymes are the catalysts of biological systems and are extremely efficient. A typical enzyme accelerates the rate of a reaction by factors of at least a million compared to the rate of the same reaction in the absence of the enzyme. In contrast to traditional catalytic enzymes, the family of cytochrome P450 (CYPs) enzymes are catalytically promiscuous and thus they possess remarkable versatility in substrates. The great diversity of reactions catalyzed by CYP enzymes appear to be based on two unique properties of these heme proteins, the ability of their iron to exist under multiple oxidation states with different reactivities and a flexible active site that can accommodate a wide variety of substrates. Herein, is a discussion of two distinct type of kinetics observed with CYP enzymes. The first example is of CYP complex kinetic profiles when multiple CYP enzymes form the sample product. The second is sequential metabolism, in other words, the formation of multiple products from one CYP enzyme. Given the degree of CYP enzyme promiscuity, it is hardly surprising that there is also a high degree of complex kinetic profiles generated during the catalytic cycle.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Koshland DE (1958) Application of a theory of enzyme specificity to protein synthesis. Proc Natl Acad Sci U S A 44(2):98–104
Albery WJ, Knowles JR (1976) Free-energy profile of the reaction catalyzed by triosephosphate isomerase. Biochemistry 15(25):5627–5631
Storm DR, Koshland DE (1970) A source for the special catalytic power of enzymes: orbital steering. Proc Natl Acad Sci U S A 66(2):445–452
Pauling L, Delbruck M (1940) The nature of the intermolecular forces operative in biological processes. Science 92(2378):77–79. https://doi.org/10.1126/science.92.2378.77
Lienhard GE (1973) Enzymatic catalysis and transition-state theory. Science 180(4082):149–154
Porter TD, Coon MJ (1991) Cytochrome P-450. Multiplicity of isoforms, substrates, and catalytic and regulatory mechanisms. J Biol Chem 266(21):13469–13472
Wienkers LC, Heath TG (2005) Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov 4(10):825–833. https://doi.org/10.1038/nrd1851
Coon MJ, Vaz AD, McGinnity DF, Peng HM (1998) Multiple activated oxygen species in P450 catalysis: contributions to specificity in drug metabolism. Drug Metab Dispos 26(12):1190–1193
de Visser SP, Ogliaro F, Sharma PK, Shaik S (2002) What factors affect the regioselectivity of oxidation by cytochrome p450? A DFT study of allylic hydroxylation and double bond epoxidation in a model reaction. J Am Chem Soc 124(39):11809–11826
Jones JP, Korzekwa KR (1996) Predicting the rates and regioselectivity of reactions mediated by the P450 superfamily. Methods Enzymol 272:326–335
Peter R, Bocker R, Beaune PH, Iwasaki M, Guengerich FP, Yang CS (1990) Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1. Chem Res Toxicol 3(6):566–573
Wynalda MA, Hutzler JM, Koets MD, Podoll T, Wienkers LC (2003) In vitro metabolism of clindamycin in human liver and intestinal microsomes. Drug Metab Dispos 31(7):878–887. https://doi.org/10.1124/dmd.31.7.878
Gorski JC, Jones DR, Wrighton SA, Hall SD (1994) Characterization of dextromethorphan N-demethylation by human liver microsomes. Contribution of the cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 48(1):173–182
Wienkers LC, Wurden CJ, Storch E, Kunze KL, Rettie AE, Trager WF (1996) Formation of (R)-8-hydroxywarfarin in human liver microsomes. A new metabolic marker for the (S)-mephenytoin hydroxylase, P4502C19. Drug Metab Dispos 24(5):610–614
He M, Rettie AE, Neal J, Trager WF (2001) Metabolism of sulfinpyrazone sulfide and sulfinpyrazone by human liver microsomes and cDNA-expressed cytochrome P450s. Drug Metab Dispos 29(5):701–711
Isoherranen N, Kunze KL, Allen KE, Nelson WL, Thummel KE (2004) Role of itraconazole metabolites in CYP3A4 inhibition. Drug Metab Dispos 32(10):1121–1131
Templeton IE, Thummel KE, Kharasch ED, Kunze KL, Hoffer C, Nelson WL, Isoherranen N (2007) Contribution of itraconazole metabolites to inhibition of CYP3A4 In Vivo. Clin Pharmacol Ther 83(1):77–85
Jeffery EH, Mannering GJ (1983) Interaction of constitutive and phenobarbital-induced cytochrome P-450 isozymes during the sequential oxidation of benzphetamine. Explanation for the difference in benzphetamine-induced hydrogen peroxide production and 455-nm complex formation in microsomes from untreated and phenobarbital-treated rats. Mol Pharmacol 23(3):748–757
Hanson KL, VandenBrink BM, Babu KN, Allen KE, Nelson WL, Kunze KL (2010) Sequential metabolism of secondary alkyl amines to metabolic-intermediate complexes: opposing roles for the secondary hydroxylamine and primary amine metabolites of desipramine, (s)-fluoxetine, and N-desmethyldiltiazem. Drug Metab Dispos 38(6):963–972. https://doi.org/10.1124/dmd.110.032391
Sugiyama K, Nagata K, Gillette JR, Darbyshire JF (1994) Theoretical kinetics of sequential metabolism in vitro. Study of the formation of 16 alpha-hydroxyandrostenedione from testosterone by purified rat P450 2C11. Drug Metab Dispos 22(4):584–591
Varon R, Havsteen BH, Valero E, Molina-Alarcon M, Garcia-Canovas F, Garcia-Moreno M (2005) Kinetic analysis of the transient phase and steady state of open multicyclic enzyme cascades. Acta Biochim Pol 52(4):765–780
Segel IH (1993) Enzyme kinetics: behavior and analysis of rapid equilibrium and steady-state enzyme systems, 1st edn. Wiley, New York
Lakowski TM, Frankel A (2009) Kinetic analysis of human protein arginine N-methyltransferase 2: formation of monomethyl- and asymmetric dimethyl-arginine residues on histone H4. Biochem J 421(2):253–261
Rane A, Wilkinson GR, Shand DG (1977) Prediction of hepatic extraction ratio from in vitro measurement of intrinsic clearance. J Pharmacol Exp Ther 200(2):420–424
Michaelis L, Menten ML, Johnson KA, Goody RS (2011) The original Michaelis constant: translation of the 1913 Michaelis-Menten paper. Biochemistry 50(39):8264–8269. https://doi.org/10.1021/bi201284u
Lineweaver H, Burk D (1934) The determination of enzyme dissociation constants. J Am Chem Soc 56(3):658–666. https://doi.org/10.1021/ja01318a036
Eadie GS (1942) The inhibition of cholinesterase by physostigmine and prostigmine. J Biol Chem 146(1):85–93
Hofstee BH (1959) Non-inverted versus inverted plots in enzyme kinetics. Nature 184:1296–1298
Nakashima A, Kawashita H, Masuda N, Saxer C, Niina M, Nagae Y, Iwasaki K (2005) Identification of cytochrome P450 forms involved in the 4-hydroxylation of valsartan, a potent and specific angiotensin II receptor antagonist, in human liver microsomes. Xenobiotica 35(6):589–602. https://doi.org/10.1080/00498250500158175
Wienkers LC, Wynalda MA (2002) Multiple cytochrome P450 enzymes responsible for the oxidative metabolism of the substituted (S)-3-phenylpiperidine, (S,S)-3-[3-(methylsulfonyl)phenyl]-1-propylpiperidine hydrochloride, in human liver microsomes. Drug Metab Dispos 30(12):1372–1377
Jones BC, Hyland R, Ackland M, Tyman CA, Smith DA (1998) Interaction of terfenadine and its primary metabolites with cytochrome P450 2D6. Drug Metab Dispos 26(9):875–882
Wienkers LC, Steenwyk RC, Sanders PE, Pearson PG (1996) Biotransformation of tirilazad in human: 1. Cytochrome P450 3A-mediated hydroxylation of tirilazad mesylate in human liver microsomes. J Pharmacol Exp Ther 277(2):982–990
Tuvesson H, Wienkers LC, Gunnarsson PO, Seidegard J, Persson R (2000) Identification of cytochrome P4503A as the major subfamily responsible for the metabolism of roquinimex in man. Xenobiotica 30(9):905–914. https://doi.org/10.1080/004982500433327
Davydov DR, Davydova NY, Rodgers JT, Rushmore TH, Jones JP (2017) Toward a systems approach to the human cytochrome P450 ensemble: interactions between CYP2D6 and CYP2E1 and their functional consequences. Biochem J 474(20):3523–3542. https://doi.org/10.1042/bcj20170543
Davydova NY, Dangi B, Maldonado MA, Vavilov NE, Zgoda VG, Davydov DR (2019) Toward a systems approach to cytochrome P450 ensemble: interactions of CYP2E1 with other P450 species and their impact on CYP1A2. Biochem J 476(23):3661–3685. https://doi.org/10.1042/bcj20190532
Nigam SK, Bush KT, Bhatnagar V, Poloyac SM, Momper JD (2020) The systems biology of drug metabolizing enzymes and transporters: relevance to quantitative systems pharmacology. Clin Pharmacol Ther 108(1):40–53. https://doi.org/10.1002/cpt.1818
Silverman RB (1988) Mechanism-based enzyme inactivation: chemistry and enzymology. CRC Press, Boca Raton
Atrakchi AH (2009) Interpretation and Considerations on the Safety Evaluation of Human Drug Metabolites. Chem Res Toxicol 22(7):1217–1220
Baillie TA (2008) Metabolism and toxicity of drugs. Two decades of progress in industrial drug metabolism. Chem Res Toxicol 21(1):129–137
Smith DA, Obach RS (2006) Metabolites and safety: what are the concerns, and how should we address them? Chem Res Toxicol 19(12):1570–1579
Smith DA, Obach RS (2009) Metabolites in Safety Testing (MIST): considerations of mechanisms of toxicity with dose, abundance, and duration of treatment. Chem Res Toxicol 22(2):267–279
Bushee JL, Argikar UA (2011) An experimental approach to enhance precursor ion fragmentation for metabolite identification studies: application of dual collision cells in an orbital trap. Rapid Commun Mass Spectrom 25(10):1356–1362. https://doi.org/10.1002/rcm.4996
Waley SG (1985) Kinetics of suicide substrates: practical procedures for determining parameters. Biochem J 227:843–849
Mayhew BS, Jones DR, Hall SD (2000) An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metab Dispos 28:1031–1037
Polasek TM, Miners JO (2008) Time-dependent inhibition of human drug metabolizing cytochromes P450 by tricyclic antidepressants. Br J Clin Pharmacol 65(1):87–97
Jones DR, Gorski JC, Hamman MA, Mayhew BS, Rider S, Hall SD (1999) Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation. J Pharmacol Exp Ther 290(3):1116–1125
McConn DJ 2nd, Lin YS, Allen K, Kunze KL, Thummel KE (2004) Differences in the inhibition of cytochromes P450 3A4 and 3A5 by metabolite-inhibitor complex-forming drugs. Drug Metab Dispos 32(10):1083–1091
Zhang X, Jones DR, Hall SD (2009) Prediction of the effect of erythromycin, diltiazem, and their metabolites, alone and in combination, on CYP3A4 inhibition. Drug Metab Dispos 37(1):150–160
Ortiz de Montellano PR (ed) (2005) Cytochrome P450: Structure, Mechanism, and Biochemistry, 3rd edn. Kluwer Academic/Plenum Publishers, New York
Venkatakrishnan K, Obach RS (2007) Drug-drug interactions via mechanism-based cytochrome P450 inactivation: points to consider for risk assessment from in vitro data and clinical pharmacologic evaluation. Curr Drug Metab 8(5):449–462
Lindeke B, Paulsen-Sorman U, Hallstrom G, Khuthier AH, Cho AK, Kammerer RC (1982) Cytochrome P-455-nm complex formation in the metabolism of phenylalkylamines. VI. Structure--activity relationships in metabolic intermediary complex formation with a series of alpha-substituted 2-phenylethylamines and corresponding N-hydroxylamines. Drug Metab Dispos 10(6):700–705
VandenBrink BM, Isoherranen N (2010) The role of metabolites in predicting drug-drug interactions: focus on irreversible cytochrome P450 inhibition. Curr Opin Drug Discov Devel 13(1):66–77
Korzekwa K, Tweedie D, Argikar UA, Whitcher-Johnstone A, Bell L, Bickford S, Nagar S (2014) A numerical method for analysis of in vitro time-dependent inhibition data. Part 2. Application to experimental data. Drug Metab Dispos 42(9):1587–1595. https://doi.org/10.1124/dmd.114.058297
Nagar S, Jones JP, Korzekwa K (2014) A numerical method for analysis of in vitro time-dependent inhibition data. Part 1. Theoretical considerations. Drug Metab Dispos 42(9):1575–1586. https://doi.org/10.1124/dmd.114.058289
Yadav J, Paragas E, Korzekwa K, Nagar S (2020) Time-dependent enzyme inactivation: Numerical analyses of in vitro data and prediction of drug-drug interactions. Pharmacol Ther 206:107449. https://doi.org/10.1016/j.pharmthera.2019.107449
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Wienkers, L.C., Rock, B.M. (2021). Multienzyme Kinetics and Sequential Metabolism. In: Nagar, S., Argikar, U.A., Tweedie, D. (eds) Enzyme Kinetics in Drug Metabolism. Methods in Molecular Biology, vol 2342. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-1554-6_4
Download citation
DOI: https://doi.org/10.1007/978-1-0716-1554-6_4
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-1553-9
Online ISBN: 978-1-0716-1554-6
eBook Packages: Springer Protocols